-
2023-507222-17-00
5
2020-07-24
Acute Myeloid Leukaemia
-
2023-506527-28-00
5
2020-06-29
Axial Spondyloarthritis
-
2024-513948-28-00
4
2020-05-08
unresectable stage III NSCLC (Non–small-cell lung cancer)
-
2024-512448-41-00
5
2020-04-01
Bronchiolitis Obliterans Syndrome in Patients post Single or post Doub
-
2022-501018-78-00
5
2020-03-23
Axial Spondyloarthritis
-
2023-508293-28-00
5
2020-02-20
Dermatomyositis
-
2024-514479-16-00
4
2019-10-28
Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma with
-
2023-506657-38-00
5
2019-10-02
Biliary Tract Carcinoma
-
2024-513762-18-00
4
2019-09-20
Primary Biliary Cholangitis (PBC)
-
2023-503956-29-00
5
2019-08-26
Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient
M
-
2023-505167-36-00
5
2019-08-05
Patients who present late on during their acquisition of the HIV-1
(Hu
-
2022-501971-24-00
5
2019-05-20
Adjuvant treatment of HCC
-
2022-502187-20-00
5
2019-04-11
Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3a detected eith
-
2023-505476-29-00
5
2019-04-05
Giant Cell Arteritis
-
2022-502747-35-00
5
2019-02-18
Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ova
-
2022-502938-30-00
5
2018-12-10
Moderate and Severe Atopic Dermatitis
-
2023-505494-32-00
5
2018-10-15
Focal segmental glomerulosclerosis (FSGS)
-
2023-508253-98-00
5
2018-10-05
Gastric or gastroesophageal junction (GEJ) adenocarcinoma
-
2023-508472-11-00
5
2018-06-13
Patients with early breast cancer
-
2023-510200-42-00
5
2017-12-06
primary sclerosing cholangitis (PSC)
-
2024-513167-68-00
5
2017-11-29
endometrial cancer
-
2023-509595-42-00
5
2017-10-31
Gastric and gastroesophageal junction (GEJ) adenocarcinoma
-
2022-501784-40-00
5
2017-05-26
Untreated Unresectable or Metastatic Urothelial Cancer
-
2024-518022-33-00
5
2016-07-15
Advanced Stage of Hodgkin Lymphoma